{"id":32696,"date":"2025-07-09T15:44:50","date_gmt":"2025-07-09T10:14:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32696"},"modified":"2025-07-09T15:44:51","modified_gmt":"2025-07-09T10:14:51","slug":"vx-880-101-forward-trial","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial","title":{"rendered":"Durable Glycemic Control and Elimination of Exogenous Insulin Use with Zimislecel (VX-880) in Patients with Type 1 Diabetes (T1D)\u2014VX-880-101 (FORWARD)"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>Zimislecel (VX-880) is an investigational stem cell-derived islet cell therapy for T1D patients with severe hypoglycemia and impaired awareness. It aims to restore insulin production and glucose regulation. Delivered via hepatic portal vein infusion, it requires immunosuppression and holds multiple regulatory designations across the US, Europe, and the UK.<\/em><\/li>\n\n\n\n<li><em>At ADA 2025, Zimislecel showed durable benefits in T1D patients; 10 of 12 were insulin-free after one year, all met HbA1c &lt;7% and &gt;70% time-in-range.&nbsp;<\/em><\/li>\n<\/ul>\n\n\n\n<p>At the <strong>American Diabetes Association (ADA)<\/strong> annual conference in Chicago, <strong>Vertex Pharmaceuticals shared encouraging results for Zimislecel in T1D<\/strong>, with the pivotal trial advancing swiftly and global regulatory filings planned for 2026.<\/p>\n\n\n\n<p><strong>ADA 2025 Coverage Abstract: FORWARD Trial in T1D<\/strong><\/p>\n\n\n\n<p>The Phase I\/II portion of the Phase I\/II\/III pivotal study evaluated Zimislecel in individuals with T1D. In Part A, participants received a half dose (0.4\u00d710\u2079 cells) via portal vein infusion, with an optional second dose within two years. Parts B and C involved a single full dose (0.8\u00d710\u2079 cells). All participants were administered glucocorticoid-free immunosuppression. Part A\u2019s primary endpoint was safety, while Part C focused on avoiding severe hypoglycemia alongside HbA1c &lt;7% or a \u22651% reduction by Days 180\u2013365. Secondary endpoints included insulin independence and safety. C-peptide detection during mixed-meal testing assessed islet function.&nbsp;<\/p>\n\n\n\n<p><strong>Results<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Efficacy (Glycemic Control and Insulin Independence)<\/strong><\/li>\n<\/ul>\n\n\n\n<p>All 12 patients who received a full dose of Zimislecel demonstrated significant clinical benefits. By Day 365, 100% achieved HbA1c &lt;7%, had no Severe Hypoglycemic Events (SHEs), and showed reduced reliance on insulin. Impressively, 10 out of 12 patients (83%) became insulin-independent. <em>These outcomes suggest that Zimislecel can restore endogenous insulin production and effectively manage glucose levels in patients with T1D.<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C-Peptide and Mixed-Meal Tolerance Test (MMTT) Outcomes<\/strong><\/li>\n<\/ul>\n\n\n\n<p>At baseline, participants had undetectable C-peptide levels, indicating no insulin production. Following Zimislecel infusion, all patients showed detectable and increasing C-peptide levels through Day 365, confirming engraftment and endogenous insulin secretion. MMTT results further showed significant improvements in both fasting and 90-min glucose levels<em>, indicating restored islet cell function and glucose responsiveness post-treatment.<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous Glucose Monitoring (CGM) Metrics<\/strong><\/li>\n<\/ul>\n\n\n\n<p>By Month 12, all participants achieved over 70% Time in Range (TIR), aligning with ADA\/EASD glycemic targets. Mean daily insulin usage declined by over 90% from baseline, and HbA1c was reduced by an average of ~1.8%. <em>These metrics support the therapy\u2019s sustained effect on glycemic stability and confirm that patients maintained optimal glucose control without frequent lows or highs.<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety and Tolerability Profile<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Zimislecel\u2019s safety profile aligned with the known effects of immunosuppressants. Most adverse events were mild or moderate; two unrelated deaths occurred. Common, manageable events included diarrhea, headache, nausea, and neutropenia.<\/p>\n\n\n\n<p><strong>KOL Views<\/strong><\/p>\n\n\n\n<p>\u201cZimislecel represents a landmark advancement in T1D care, moving beyond symptom management to actual restoration of endogenous insulin production. Early clinical responses signal durable glycemic control with eliminated severe hypoglycemia, suggesting a foundational shift in therapy. As a result, this innovation may redefine standards of care, introducing a regenerative approach that could sustainably reduce reliance on exogenous insulin and significantly enhance patient quality of life.\u201d<strong> <\/strong><strong>\u2013 Expert Opinion<\/strong><\/p>\n\n\n\n<p>\u201cAs Vertex finalizes its pivotal trial and prepares for regulatory submissions, Zimislecel moves closer to broader use. Regulatory designations and scale-up efforts signal strong momentum, highlighting its curative potential in type 1 diabetes.\u201d<strong> \u2013 Expert Opinion<\/strong><\/p>\n\n\n\n<p><strong>Conclusion<\/strong><\/p>\n\n\n\n<p>The latest data on Zimislecel highlight its transformative potential in treating T1D, offering sustained glycemic control and insulin independence in the majority of participants. All individuals with one year of follow-up achieved ADA-recommended targets, with 83% eliminating the need for insulin. As Vertex nears completion of its pivotal trial, the company is preparing for global regulatory submissions in 2026. With multiple regulatory designations\u2014RMAT and Fast Track (FDA), PRIME (EMA), and Innovation Passport (UK MHRA)\u2014already secured, and advanced manufacturing and commercial planning underway, Zimislecel represents a major step forward in stem cell-derived islet cell therapy. Ongoing research into gene-edited and hypoimmune approaches may further enhance future treatment strategies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the American Diabetes Association (ADA) annual conference in Chicago, Vertex Pharmaceuticals shared encouraging results for Zimislecel in T1D, with the pivotal trial advancing swiftly and global regulatory filings planned for 2026. ADA 2025 Coverage Abstract: FORWARD Trial in T1D The Phase I\/II portion of the Phase I\/II\/III pivotal study evaluated Zimislecel in individuals with [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32698,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[22599],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-32696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-ada-annual-conference","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>VX-880-101 FORWARD Trial | ADA 2025<\/title>\n<meta name=\"description\" content=\"Latest data on Zimislecel highlight its transformative potential, offering glycemic control &amp; insulin independence in majority participants.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VX-880-101 FORWARD Trial | ADA 2025\" \/>\n<meta property=\"og:description\" content=\"Latest data on Zimislecel highlight its transformative potential, offering glycemic control &amp; insulin independence in majority participants.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T10:14:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T10:14:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09154441\/vx-880-101-forward-trial.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"VX-880-101 FORWARD Trial | ADA 2025","description":"Latest data on Zimislecel highlight its transformative potential, offering glycemic control & insulin independence in majority participants.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial","og_locale":"en_US","og_type":"article","og_title":"VX-880-101 FORWARD Trial | ADA 2025","og_description":"Latest data on Zimislecel highlight its transformative potential, offering glycemic control & insulin independence in majority participants.","og_url":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-09T10:14:50+00:00","article_modified_time":"2025-07-09T10:14:51+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09154441\/vx-880-101-forward-trial.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial","url":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial","name":"VX-880-101 FORWARD Trial | ADA 2025","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09154441\/vx-880-101-forward-trial.png","datePublished":"2025-07-09T10:14:50+00:00","dateModified":"2025-07-09T10:14:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Latest data on Zimislecel highlight its transformative potential, offering glycemic control & insulin independence in majority participants.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/vx-880-101-forward-trial#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09154441\/vx-880-101-forward-trial.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09154441\/vx-880-101-forward-trial.png","width":466,"height":284,"caption":"vx-880-101-forward-trial"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09154441\/vx-880-101-forward-trial-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">ADA Annual Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ADA Annual Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Jul 9, 2025","modified":"Updated on Jul 9, 2025"},"absolute_dates_time":{"created":"Posted on Jul 9, 2025 3:44 pm","modified":"Updated on Jul 9, 2025 3:44 pm"},"featured_img_caption":"vx-880-101-forward-trial","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32696"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32696\/revisions"}],"predecessor-version":[{"id":32697,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32696\/revisions\/32697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32698"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32696"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32696"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}